Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer

References

• NCCN Guidelines Version 3.2013 Colon Cancer. National Comprehensive Cancer Network. Available at http://nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• NCCN Guidelines Version 4.2013 Rectal Cancer. National Comprehensive Cancer Network. Available at http://nccn.org/professionals/physician_gls/f_guidelines.asp.
   Google Scholar
• Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866–75.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37.
   PubMed Web of Science ®Google Scholar
• Michaelson R, Kemeny N, Young C. Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma. Cancer Treat Rep 1982;66:1757–8.
   PubMedGoogle Scholar
• Wils JA. Phase II trial of 4'-epi-doxorubicin in metastatic colorectal carcinoma. Invest New Drugs 1984;2:397–9.
   PubMed Web of Science ®Google Scholar
• Ferrazzi E, Pappagallo GL, Nicoletto O, Fornasiero A, Refatti F, Cartei G, et al. Phase II evaluation of 4'epi-doxorubicin in patients with metastatic colorectal carcinoma. Tumori 1984;70:297–300.
   PubMed Web of Science ®Google Scholar
• Holdener EE, Hansen HH, Host H, Bruntsch U, Cavalli F, Renard J, et al. Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC). Invest New Drugs 1985;3:63–6.
   PubMed Web of Science ®Google Scholar
• Moreno NJ, Murillo E, Duque A, Jimeno J, Iglesias L, Romero F, et al. Epirubicin in rectal cancer. Chemioterapia 1988;7:189–94.
   PubMedGoogle Scholar
• Greidanus J, Willemse PH, Sleijfer DT, Mulder NH, Verschueren RC, Nieweg R, et al. Phase II study of a 21-day continuous infusion schedule with epirubicin in metastatic colorectal cancer. Eur J Cancer Clin Oncol 1988;24:801–2.
   PubMedGoogle Scholar
• Vorobiof DA, Falkson G. Phase II study of high-dose 4'-epidoxorubicin in the treatment of advanced gastrointestinal cancer. Eur J Cancer Clin Oncol 1989;25:563–4.
   PubMedGoogle Scholar
• Molinaro P, Lafleur F, Blum RH. A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. Am J Clin Oncol 1989;12:332–4.
   PubMed Web of Science ®Google Scholar
• Alberola V, Garcia CJ, Jimeno J, Fernandez MC, Herranz C, Macheng I, et al. Phase II study with high doses of epirubicin in patients with advanced rectal cancer. Tumori 1990;76:503–4.
   PubMed Web of Science ®Google Scholar
• Rosenthal MA, Green M, Wiernik P, Borden EC, Marsh JC, Haller DG. Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group. Am J Clin Oncol 1998;21:509–12.
   PubMed Web of Science ®Google Scholar
• Ganzina F. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 1983;10:1–22.
   PubMed Web of Science ®Google Scholar
• Pommier Y, Leo E, Zhang H, Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010;17:421–33.
   PubMed Web of Science ®Google Scholar
• Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, et al. The role of topoisomerase. II alpha in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures. Breast Cancer Res Treat 2011;129:839–48.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol 2011;12:1134–42.
   PubMed Web of Science ®Google Scholar
• Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007;60:768–72.
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, McArdle CS, Moesgaard F, Schulze S, Thorup J, Wille-Jorgensen P, et al. The effect of ranitidine on long-term survival in primary colorectal cancer. A 40 months interim analysis. GI Cancer 1998;2:227–33.
   Web of Science ®Google Scholar
• Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg 2002;89:1416–22.
   PubMed Web of Science ®Google Scholar
• Romer MU, Nygard SB, Christensen IJ, Nielsen SL, Nielsen KV, Muller S, et al. Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol Oncol 2012;7:101–11.
   PubMed Web of Science ®Google Scholar
• Key G, Becker MH, Baron B, Duchrow M, Schluter C, Flad HD, et al. New Ki-67-equivalent murine monoclonal antibodies (MIB 1–3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993;68:629–36.
   PubMed Web of Science ®Google Scholar
• Nielsen KV, Ejlertsen B, Moller S, Jensen MB, Balslev E, Muller S, et al. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status. Mol Oncol 2012;6:88–97.
   PubMed Web of Science ®Google Scholar
• Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med 2012;10:51.
   PubMed Web of Science ®Google Scholar
• Marchio C, Lambros MB, Gugliotta P, Di Cantogno LV, Botta C, Pasini B, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? a fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 2009;219:16–24.
   PubMed Web of Science ®Google Scholar
• Viale G. Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J Pathol 2009;219:1–2.
   PubMed Web of Science ®Google Scholar
• Moelans CB, Reis-Filho JS, van Diest PJ. Implications of rarity of chromosome 17 polysomy in breast cancer. Lancet Oncol 2011;12:1087–9.
   PubMed Web of Science ®Google Scholar
• Tumorscape copy number alterations across multiple cancers types: broad institute. tumorscape release 1.6. Available at http://broadinstitute.org/tumorscape/pages/portalHome.jsf.
   Google Scholar
• Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007;104:20007–12.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899–905.
   PubMed Web of Science ®Google Scholar
• Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, et al. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 2009;10:267–77.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118–45.
   PubMed Web of Science ®Google Scholar
• Mitelman database of chromosome aberrations and gene fusions in cancer: national cancer institute. Cancer genome anatomy project. Available at http://cgap.nci.nih.gov/Chromosomes/Mitelman.
   Google Scholar